Disposition of 4608 shares by William Young of Smart Sand at 1.9 subject to Rule 16b-3

VRTX34 Stock  BRL 701.09  2.91  0.42%   
About 54% of Vertex Pharmaceuticals' investor base is interested to short. The analysis of current outlook of investing in Vertex Pharmaceuticals Incorporated suggests that many traders are impartial regarding Vertex Pharmaceuticals' prospects. The current market sentiment, together with Vertex Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Vertex Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Smart Sand Officer: Chief Operating Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 4608 common stock at 1.9 of Smart Sand by William Young on 18th of March 2024. This event was filed by Smart Sand with SEC on 2024-03-17. Statement of changes in beneficial ownership - SEC Form 4. William Young currently serves as executive vice president of sales and logistics of Smart Sand

Vertex Pharmaceuticals Fundamental Analysis

We analyze Vertex Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Gross Profit

Gross Profit Comparative Analysis

Vertex Pharmaceuticals is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Vertex Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vertex Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics with similar companies.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Valuation
Check real value of public entities based on technical and fundamental data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Fundamental Analysis
View fundamental data based on most recent published financial statements
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope